Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar Biotoday (26.75) Submitted: 5/18/2011 10:34:38 AM : Outperform Start Price: $2.21 AEZS Score: -68.79

Buying on pullback

Report this Post 1 Comment
Member Avatar canesmonkey (< 20) Submitted: 7/27/2011 3:58:44 PM
Recs: 0

So are you buying today ????

Report this Post

Featured Broker Partners


Advertisement